Clinical Trial Update: An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy [Phase 2]

View source ↗

Summary

Open-label extension study results for RWJ-333369 in epilepsy have completed Phase 2 evaluation, focusing on safety and effectiveness in patients with partial e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial Epilepsy

Drugs mentioned

• RWJ 333369 (RWJ-333369)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Epilepsy, Epilepsies, Partial | Phase 2 | Status: COMPLETED